Location History:
- Cranbury, NJ (US) (1997)
- West Windsor, NJ (US) (2008)
Company Filing History:
Years Active: 1997-2008
Title: Ramakrishna Seethala: Innovator in Enzyme Assays and Anorexiant Agents
Introduction
Ramakrishna Seethala is a notable inventor based in West Windsor, NJ (US). He has made significant contributions to the field of enzyme assays and the development of anorexiant agents. With a total of 2 patents, his work has implications for both scientific research and medical applications.
Latest Patents
One of his latest patents is the "Scintillation proximity assay method of measuring acetyl CoA carboxylase enzyme activity." This invention relates to enzyme assays and provides a rapid, sensitive, reliable, and robust homogeneous assay for acetyl CoA carboxylase activity. The assay couples ACC and FAS, allowing for the detection of palmitic acid through scintillation counting. This method is particularly suitable for high-throughput screening and aids in identifying modulators of ACC activity.
Another significant patent is focused on "Dihydropyridine NPY antagonists: piperazine derivatives." This series of non-peptidergic antagonists of NPY has been synthesized and includes piperazine and homopiperazine derivatives of 4-phenyl-1,4-dihydropyridines. These compounds are expected to act as effective anorexiant agents, promoting weight loss and treating eating disorders by antagonizing NPY-induced feeding behavior.
Career Highlights
Ramakrishna Seethala is currently employed at Bristol-Myers Squibb Company, where he continues to innovate and contribute to the field of biochemistry and pharmacology. His work is instrumental in advancing research and developing new therapeutic agents.
Collaborations
He has collaborated with notable coworkers such as Graham S Poindexter and Marc A Bruce, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Ramakrishna Seethala's contributions to enzyme assays and anorexiant agents highlight his role as an influential inventor in the scientific community. His patents reflect a commitment to advancing medical research and improving therapeutic options.